Glenmark Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2014
The company has posted a rise of 78.61% in its net profit at Rs 151.66 crore for the quarter ended March 31, 2014 as compared to Rs 84.91 crore for the same quarter in the previous year. Total income of the company increased by 34.28% at Rs 687.25 crore for quarter under review as compared to Rs 511.79 crore for the quarter ended March 31, 2013.
On consolidated basis, the company has reported 74.97% fall in its net profit at Rs 43.06 crore for the quarter ended March 31, 2014 as compared to Rs 172.08 crore for the same quarter in the previous year. However, total income of the company has increased by 27.09% at Rs 1691.48 crore for quarter under review as compared to Rs 1330.90 crore for the quarter ended March 31, 2013.
For the year ended March 31, 2014, the company has posted a jump of 12.35% in its net profit at Rs 433.82 crore as compared to Rs 386.10 crore for the same period in the previous year. Total income of company improved by 14.64% at Rs 2368.03 crore for year under review as compared to Rs 2065.54 crore for the period ended March 31, 2013.
For the year ended March 31, 2014, on the consolidated basis, the company has posted a fall of 12.54% in its net profit at Rs 542.27 crore as compared to Rs 620.03 crore for the same period in the previous year. However, total income of company has increased by 19.78% at Rs 6016.68 crore for year under review as compared to Rs 5023.08 crore in the previous fiscal.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: